137 related articles for article (PubMed ID: 9004298)
1. Clinical evaluation of the bone marrow imaging agent 99Tcm-phytate in the detection of bone metastases.
Chang CP; Liu RS; Yu SM; Wynchank S; Chu LS; Shiau HY; Cheng TC
Nucl Med Commun; 1996 Dec; 17(12):1030-4. PubMed ID: 9004298
[TBL] [Abstract][Full Text] [Related]
2. 99Tcm-HMPAO-labelled leucocytes for bone marrow scintigraphy and evaluation of skeletal lesions. Comparison with 99Tcm-HSA colloid results.
Bourgeois P; Demonceau G; Stegen M; Ferremans W
Nucl Med Commun; 1991 Jul; 12(7):621-7. PubMed ID: 1923153
[TBL] [Abstract][Full Text] [Related]
3. Tc-99m phytate bone marrow scintigraphy showing multiple areas of focal hyperactivity in a patient with lung cancer. A case report.
Chang CP; Chu LS; Liu RS; Yu SM; Yeh SH
Clin Nucl Med; 1995 Jun; 20(6):501-4. PubMed ID: 7648731
[TBL] [Abstract][Full Text] [Related]
4. Detection of metastatic bone lesions in patients with prostate carcinoma: 99Tcm-monoclonal antibody imaging.
Kiraç S; Duman Y; Cüreklibatur I; Yüksel D; Nazli O; Günaydin G; Taner M
Nucl Med Commun; 1997 Oct; 18(10):968-73. PubMed ID: 9392800
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of metastatic bone disease with pentavalent 99Tc(m)-dimercaptosuccinic acid: a comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions.
Sahin M; Basoglu T; Bernay I; Yapici O; Canbaz F; Yalin T
Nucl Med Commun; 2000 Mar; 21(3):251-8. PubMed ID: 10823327
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of a technetium-99m bone imaging agent based on the vicinal diphosphonate 1,2-diphosphonoethyleneglycol (DPEG).
Pauwels EK; Camps JA; Blom J; Hermans J; Kelly JD; Cumming SA; Blackburn GM; Rashid A
Nucl Med Commun; 1985 Nov; 6(11):739-45. PubMed ID: 3831848
[TBL] [Abstract][Full Text] [Related]
7. The usefulness of bone-marrow scintigraphy in the detection of bone metastasis from prostatic cancer.
Otsuka N; Fukunaga M; Sone T; Yoneda M; Saito N; Tanaka H; Tomomitsu T; Yanagimoto S; Muranaka A; Morita R
Eur J Nucl Med; 1985; 11(8):319-22. PubMed ID: 4076240
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 99Tcm-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer.
Coleman RE; Meier CA; Rubens RD; Fogelman I
Nucl Med Commun; 1988 Jul; 9(7):481-5. PubMed ID: 3173907
[TBL] [Abstract][Full Text] [Related]
9. 99Tcm-MDP and 99Tcm-DPD in pathologic bone lesions. A visual and quantitative comparison.
Lantto T; Vorne M; Mokka R; Vähätalo S
Acta Radiol; 1987; 28(5):631-3. PubMed ID: 2960361
[TBL] [Abstract][Full Text] [Related]
10. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
Bushnell DL; Madsen M; Kahn D; Nathan M; Williams RD
Nucl Med Commun; 1999 Oct; 20(10):875-81. PubMed ID: 10528290
[TBL] [Abstract][Full Text] [Related]
11. [Bone marrow scintigraphy using radiocolloids in bone metastases. Sensitivity, specificity, reliability and indications].
Fritz P; Adolph J; Bubeck B; Georgi P; zum Winkel K
Rofo; 1986 Jun; 144(6):689-95. PubMed ID: 3012705
[TBL] [Abstract][Full Text] [Related]
12. 99Tcm-citrate: a new bone imaging radiopharmaceutical.
Bhatnagar A; Mishra P; Sharma R; Chuttani K; Chakravarty K; Jain CM; Mondal A; Chopra MK; Gupta A
Nucl Med Commun; 1999 Nov; 20(11):1067-76. PubMed ID: 10572918
[TBL] [Abstract][Full Text] [Related]
13. 99Tcm-labelled chimeric human/mouse anti-granulocyte antibody bone marrow scintigraphy: a preliminary clinical study.
Higuchi T; Inoue T; Sarwar M; Oriuchi N; Karasawa M; Naruse T; Yamanaka H; Watanabe T; Chung JK; Endo K
Nucl Med Commun; 1998 May; 19(5):463-74. PubMed ID: 9853336
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer.
Lacić M; Bokulić T; Lukac J; Kovacić K; Baum RP; Kusić Z
Nucl Med Commun; 1999 Feb; 20(2):135-43. PubMed ID: 10088162
[TBL] [Abstract][Full Text] [Related]
15. Colloid scintigraphy showing red bone marrow extension in patients with prostatic carcinoma.
Rudberg U; Udén R; Ahlbäck SO
Acta Radiol; 1992 Mar; 33(2):97-102. PubMed ID: 1562417
[TBL] [Abstract][Full Text] [Related]
16. The role of 99Tcm-sestamibi scintigraphy in the staging and prediction of the therapeutic response of stage IV neuroblastoma: comparison with 131I-MIBG and 99Tcm-MDP scintigraphy.
Burak Z; Yüksel DA; Cetingül N; Kantar M; Ozkiliç H; Moretti JL
Nucl Med Commun; 1999 Nov; 20(11):991-1000. PubMed ID: 10572908
[TBL] [Abstract][Full Text] [Related]
17. Pentavalent 99Tcm-DMSA imaging in patients with bone metastases.
Lam AS; Kettle AG; O'Doherty MJ; Coakley AJ; Barrington SF; Blower PJ
Nucl Med Commun; 1997 Oct; 18(10):907-14. PubMed ID: 9392790
[TBL] [Abstract][Full Text] [Related]
18. Uptake of 99Tcm-MDP in lung metastasis from osteosarcoma: clinical and animal studies.
Tsuji T; Yamamuro T; Kotoura Y; Matsumoto M; Tanaka H; Tanaka C; Toguchida J; Endo K; Sakahara H; Koizumi M
Nucl Med Commun; 1988 Dec; 9(12):947-54. PubMed ID: 3217065
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.
Limouris GS; Voliotopoulos V; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1615-8. PubMed ID: 9179204
[TBL] [Abstract][Full Text] [Related]
20. Technetium-99m MDP scintigraphy. An insensitive tool for the detection of bone marrow metastases.
Gulenchyn KY; Papoff W
Clin Nucl Med; 1987 Jan; 12(1):45-6. PubMed ID: 3815996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
